Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23

American Journal of Nephrology

Volumn 37, Issue 3, 2013, Pages 183-190

  Montford, John R ^a   Chonchol, Michel ^a   Cheung, Alfred K ^c,d   Kaufman, James S ^c   Greene, Tom ^d,f   Roberts, William L ^e   Smits, Gerard ^a   Kendrick, Jessica ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Body mass index; Dyslipidemia; Fibroblast growth factor 23; Hemodialysis

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 23; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; SERUM ALBUMIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; AGE; DEATH; GENDER; LINEAR REGRESSION ANALYSIS; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RACE; UREMIA;

AGED; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 84874007754     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346941     Document Type: Article

References (25)

1. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
2. Prie D, Urena Torres P, Friedlander G: Latest findings in phosphate homeostasis. Kidney Int 2009; 75: 882-889.
3. Kurosu H, Kuro-O M: The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009; 299: 72-78.
4. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson K: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279.
5. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
6. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
7. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
8. Kendrick J, Cheung AK, Kaufman J, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: Elevated FGF-23 associates with death, cardiovascular events and dialysis initiation. J Am Soc Nephrol 2011; 22: 1913-1922.
9. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE: Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011; 31: 219-227.
10. Fukumoto S: Actions and mode of actions of FGF19 subfamily members. Endocr J 2008; 55: 23-31.
11. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease J Am Soc Nephrol 2007; 18: 1246-1261.
12. Kopple JD, Zhu X, Lew NL, Lowrie EG: Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56: 1136-1148.
13. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16: 2386-2394.
14. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-1170.
15. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663.
16. Kopple JD: Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients . ASAIO J 1997; 43: 246-250.
17. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Disease 1998; 6: 997-1006.
18. Kamyar KZ, Abbot KC, Salahudeen AK, Kilpatrick RD, Horwich TB: Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-554.
19. Yan LL, Daviglus ML, Liu K, Stamler J, Wang R, Pirzada A, Garside DB, Dyer AR, Van Horn L, Liao Y, Fries JF, Greenland P: Midlife body mass index and hospitalization and mortality in older age. JAMA 2006; 295: 190-198.
20. Ashikaga E, Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Matsumoto K, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T: Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial 2010; 14: 315-322.
21. Jorde R, Grimnes G: Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011; 50: 303-312.
22. Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny C, Levi M: Vitamin D receptor agonist doxercalciferol modulates dietary fatinduced renal disease and renal lipid metabolism. Am J Physiol Ren Physiol 2011; 300:F801-F810.
23. Yamashita T, Yoshioka M, Itoh N: Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277: 494-498.
24. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M: Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687-26695.
25. Liu S, Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-1647.